年間 4 号発行
ISSN 印刷: 0893-9675
ISSN オンライン: 2162-6448
Indexed in
siRNA: A Potential Tool for Future Breast Cancer Therapy?
要約
The siRNA technology is a promising research tool for use in functional genomics, and it also shows potential for use in future therapy. Thus far, siRNAs have been used to specifically silence disease-associated alleles in animal models. The technology is still quite new, and the biological mechanisms underlying RNAi and siRNA-mediated knockdown of gene expression are not yet fully understood. The main issues when siRNAs are designed are efficiency and specificity, and it is of great importance to consider possible off-target effects in the siRNA design. One major challenge in siRNA-based therapy is the development of systems for efficient delivery to the target cells. A large number of tools have, over the last few years, been designed for the delivery of DNA and RNA for gene therapy, and extensive efforts are now placed into developing clinical applications of siRNAs in a range of human diseases, including breast cancer.
-
Huang Wei-Yi, Chen Dong-Hui, Ning Li, Wang Li-Wei, siRNA Mediated Silencing of NIN1/RPN12 Binding Protein 1 Homolog Inhibits Proliferation and Growth of Breast Cancer Cells, Asian Pacific Journal of Cancer Prevention, 13, 5, 2012. Crossref
-
Reece Lisa M., Sankaranarayanan Kavitha, Kathirvelu Priyadarshan, Cooper Christy, Sundararajan Raji, Leary James F., Targeted delivery of siRNA and other difficult to transfect molecules using electroporation: current status and future scope, in Electroporation-Based Therapies for Cancer, 2014. Crossref
-
Shilo Shani, Roy Sashwati, Khanna Savita, Sen Chandan K., MicroRNA in Cutaneous Wound Healing: A New Paradigm, DNA and Cell Biology, 26, 4, 2007. Crossref
-
Yang Hongjian, Lu Yue, Zheng Yabing, Yu Xingfei, Xia Xianghou, He Xiangming, Feng Weiliang, Xing Lei, Ling Zhiqiang, shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells, Cancer Chemotherapy and Pharmacology, 73, 3, 2014. Crossref
-
ElHazzat Jallal, El-sayed Mohamed E. H., Advances in Targeted Breast Cancer Therapy, Current Breast Cancer Reports, 2, 3, 2010. Crossref
-
Akhtar Saghir, Benter Ibrahim, Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity, Advanced Drug Delivery Reviews, 59, 2-3, 2007. Crossref
-
Kumari Avnesh, Kumar Vineet, Yadav Sudesh Kumar, Nanocarriers: a tool to overcome biological barriers in siRNA delivery, Expert Opinion on Biological Therapy, 11, 10, 2011. Crossref
-
Baoum Abdulgader, Ovcharenko Dmitriy, Berkland Cory, Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing, International Journal of Pharmaceutics, 427, 1, 2012. Crossref
-
Braicu Cornelia, Pileczki Valentina, Pop Laura, Petric Roxana Cojocneanu, Chira Sergiu, Pointiere Eve, Achimas-Cadariu Patriciu, Berindan-Neagoe Ioana, Deb Sumitra, Dual Targeted Therapy with p53 siRNA and Epigallocatechingallate in a Triple Negative Breast Cancer Cell Model, PLOS ONE, 10, 4, 2015. Crossref
-
Darvishi Behrad, Farahmand Leila, Majidzadeh-A Keivan, Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer, Molecular Therapy - Nucleic Acids, 7, 2017. Crossref
-
Li Jie, Zhou Tao, Liu Liang, Ju Ying Chao, Chen Yue Tong, Tan Zi Rui, Wang Jing, The regulatory role of Annexin 3 in a nude mouse bearing a subcutaneous xenograft of MDA-MB-231 human breast carcinoma, Pathology - Research and Practice, 214, 10, 2018. Crossref
-
Strong Theresa V., Curiel David T., Gene Therapy for Breast Cancer, in The Breast, 2009. Crossref
-
Hu XiaoLin, Li Sen, He Yan, Ai Ping, Wu Shaoyong, Su Yonglin, Li Xiaolin, Cai Lei, Peng Xingchen, Antitumor and antimetastatic activities of a novel benzothiazole-2-thiol derivative in a murine model of breast cancer, Oncotarget, 8, 7, 2017. Crossref
-
Alshamsan Aws, Haddadi Azita, Incani Vanessa, Samuel John, Lavasanifar Afsaneh, Uludağ Hasan, Formulation and Delivery of siRNA by Oleic Acid and Stearic Acid Modified Polyethylenimine, Molecular Pharmaceutics, 6, 1, 2009. Crossref
-
Shao Y, Liu Y, Shao C, Hu J, Li X, Li F, Zhang L, Zhao D, Sun L, Zhao X, Kopecko D J, Kalvakolanu D V, Li Y, Xu D Q, Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein, Cancer Gene Therapy, 17, 12, 2010. Crossref